Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
IPO Year: 2018
Exchange: NASDAQ
Website: vaccinex.com
8-K - VACCINEX, INC. (0001205922) (Filer)
8-K - VACCINEX, INC. (0001205922) (Filer)
10-Q - VACCINEX, INC. (0001205922) (Filer)
8-K - VACCINEX, INC. (0001205922) (Filer)
8-K - VACCINEX, INC. (0001205922) (Filer)
424B3 - VACCINEX, INC. (0001205922) (Filer)
EFFECT - VACCINEX, INC. (0001205922) (Filer)
S-3 - VACCINEX, INC. (0001205922) (Filer)
8-K - VACCINEX, INC. (0001205922) (Filer)
10-Q - VACCINEX, INC. (0001205922) (Filer)
Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer's disease at the Alzheimer's Association International Conference in Philadelphia, July 28- Aug 1, 2024. Eric Siemers, MD, Principal Investigator, will present results of the study in a Featured Research Session.
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) shares increased by 33.33% to $2.8. The company's market cap stands at $72.6 million. Annovis Bio (NYSE:ANVS) stock increased by 21.33% to $7.28. The market value of their outstanding shares is at $81.3 million. Vaccinex (NASDAQ:VCNX) stock increased by 20.96% to $6.29. The market value of their outstanding shares is at $9.9 million. Genprex (NASDAQ:GNPX) stock moved upwards by 19.42% to $2.89. The company's market cap stands at $6.0 million. Purple Biotech (NASDAQ:PPBT) shares moved upwards b
Gainers Cue Health (NASDAQ:HLTH) stock moved upwards by 32.4% to $0.12 during Monday's pre-market session. The market value of their outstanding shares is at $19.8 million. SCWorx (NASDAQ:WORX) shares increased by 25.53% to $2.36. The company's market cap stands at $2.8 million. Innovative Eyewear (NASDAQ:LUCY) stock rose 19.62% to $0.22. The company's market cap stands at $3.8 million. Vaccinex (NASDAQ:VCNX) stock rose 17.86% to $6.07. The market value of their outstanding shares is at $9.6 million. Guardant Health (NASDAQ:GH) shares increased by 15.35% to $26.3. The company's market cap stands at $3.2 billion. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 14.63% to $4.22. The co
Vaccinex (NASDAQ:VCNX) reported quarterly losses of $(2.94) per share. The company reported $104.00 thousand in sales this quarter. This is a 81.09 percent decrease over sales of $550.00 thousand the same period last year.
Gainers Lantern Pharma (NASDAQ:LTRN) shares rose 14.3% to $7.04 during Friday's after-market session. The company's market cap stands at $75.7 million. As per the press release, Q1 earnings came out yesterday. Vaccinex (NASDAQ:VCNX) shares moved upwards by 7.82% to $6.2. The market value of their outstanding shares is at $9.8 million. Purple Biotech (NASDAQ:PPBT) shares increased by 7.44% to $0.55. The market value of their outstanding shares is at $14.3 million. Dominari Holdings (NASDAQ:DOMH) stock moved upwards by 5.21% to $2.22. The company's market cap stands at $13.1 million. Alterity Therapeutics (NASDAQ:ATHE) stock increased by 4.97% to $2.11. The market value of their outstandi
Gainers Embecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out today. Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 36.28% to $1.02. The market value of their outstanding shares is at $154.2 million. The company's, Q1 earnings came out yesterday. G1 Therapeutics (NASDAQ:GTHX) shares rose 35.08% to $5.79. The company's market cap stands at $302.9 million. Vaccinex (NASDAQ:VCNX) shares rose 31.75% to $7.51. The market value of their outstanding shares is at $11.8 million. Zai Lab (NASDAQ:ZLAB) stock increased by 25.28% to $20.76. The company's
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4/A - VACCINEX, INC. (0001205922) (Issuer)
4/A - VACCINEX, INC. (0001205922) (Issuer)
4/A - VACCINEX, INC. (0001205922) (Issuer)
4/A - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13G - VACCINEX, INC. (0001205922) (Subject)
SC 13G/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13G - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (NASDAQ:VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Our Company recently announced positive results of the phase 1b/2 study of its lead product, pepinemab, in early stages of Alzheimer's disease (AD). The purpose of this report is to share additional data related to cognitive effects that may help clarify the goals of this study, how well it succeeded, and how this success supports continued development of pepinemab in AD and other neurodegenerative diseases including Huntington's Disease (HD), which was the focus of a larger previously
Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer's disease from early stage Mild Cognitive Impairment Findings echo previous phase 2 results in Huntington's disease based on similarities to neuroimmune pathology in Alzheimer's ROCHESTER, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering treatment of Alzheimer's disease (AD) with anti-Semaphorin 4D (SEMA4D) antibody, today announced positive results of its early stage SIGNAL-AD clinical trial of pepinemab antibody in AD. Topline results were presented by Eric Siemers, MD, Principal Investigator of
ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer's disease at the Alzheimer's Association International Conference in Philadelphia, July 28- Aug 1, 2024. Eric Siemers, MD, Principal Investigator, will present results of the study in a Featured Research Session. Presentation title: Results of SIGNAL-AD, a randomized, phase 1b/2 trial to eva
Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that the last patient completed their last visit in its randomized, placebo-controlled double-blind study of pepinemab treatment for Alzheimer's disease. What can we expect to learn from this study? Vaccinex scie
Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer's Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update on its key program for Alzheimer's disease. Treatment with pepinemab believed to halt or slow progression of neurodegenerative disease: Vaccinex expects to complete the pla
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs. Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer's disease and Head and Neck Cancer. Alzheimer's Dise
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease and cancer through the inhibition of SEMA4D, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant. T
Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets. Within the last 3 m
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholders held on February 8, 2024, the Company's stockholders approved a proposal to authorize a reverse stock split of the Company's common stock, at a
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, including entities affiliated with the Chairman of the Company's Board of Directors and the Company's Chief Executive Officer. The securities purchase agreement for the financing provides for the sale of an
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)